```html

Xanthoma of the Palmar Creases – A Complete Medical Guide

Overview

Xanthoma of the palmar creases (also called palmar xanthoma or palmar crease xanthoma) is a rare cutaneous manifestation characterized by yellow‑orange, slightly elevated plaques that follow the natural lines (creases) of the palms. These lesions are composed of lipid‑laden macrophages (foam cells) that accumulate in the dermis.

Although the condition itself is uncommon, it serves as an important visual clue for underlying metabolic or genetic disorders—most notably type III (familial) hyperlipoproteinemia and other severe dyslipidemias. Because it often appears before systemic symptoms, recognizing palmar xanthomas can lead to earlier diagnosis and treatment of life‑threatening cardiovascular disease.

Who it affects: The majority of cases are reported in adults aged 20–50 years, with a slight male predominance (≈ 55 %). However, pediatric cases have been described, especially in children with familial lipid disorders.

Prevalence: Precise epidemiologic data are limited, but palmar crease xanthomas occur in < 5 % of patients with type III hyperlipoproteinemia and are seen in < 2 % of individuals with other severe hyperlipidemias (Mayo Clinic, 2022). Their rarity makes them a “red‑flag” sign rather than a common disease.

Symptoms

Palmar crease xanthomas are usually asymptomatic, but patients may notice the following:

• Yellow‑orange plaques that follow the major palmar flexion lines (distal palmar crease, thenar crease, hypothenar crease).
• Texture: plaques are soft to firm, slightly raised, and may feel waxy or greasy.
• Size: individual lesions range from a few millimetres to several centimetres; they often coalesce into larger patches.
• Location: predominantly the palms; occasional involvement of the fingertips, soles, and occasionally the dorsal hand.
• Pruritus or tenderness: uncommon, but some patients report mild itching or tenderness after prolonged pressure (e.g., typing).
• Associated systemic signs (when an underlying lipid disorder is present):
  • Corneal arcus (gray‑white ring around the cornea)
  • Tendon xanthomas (e.g., Achilles, extensor tendons)
  • Pancreatitis (in severe hypertriglyceridemia)
  • Early‑onset atherosclerotic cardiovascular disease

Causes and Risk Factors

Palmar xanthomas result from the deposition of lipids in dermal macrophages. The underlying cause is almost always a disorder of lipid metabolism:

Primary (genetic) causes

• Familial hyperlipoproteinemia type III (dysbetalipoproteinemia) – caused by APOE ε2/ε2 homozygosity; patients have elevated chylomicron remnants and β‑VLDL.
• Familial combined hyperlipidemia – high LDL and VLDL levels.
• Familial hypertriglyceridemia – markedly raised triglycerides (>500 mg/dL).
• Familial hypercholesterolemia (FH) – rare but can produce palmar lesions when LDL is extremely high.

Secondary (acquired) causes

• Uncontrolled diabetes mellitus (especially type 2) leading to dyslipidemia.
• Chronic liver disease (non‑alcoholic fatty liver disease, cholestasis).
• Nephrotic syndrome – massive protein loss triggers hepatic lipoprotein synthesis.
• Medications that raise lipids (e.g., glucocorticoids, certain antiretrovirals, retinoids).
• Obesity and metabolic syndrome.

Risk factors

• Family history of early‑onset coronary artery disease or known lipid disorder.
• Smoking – worsens atherosclerotic risk and may accelerate lesion formation.
• Sedentary lifestyle and high‑saturated‑fat diet.
• Ethnicity: Certain APOE variants are more common in Mediterranean and Middle‑Eastern populations.

Diagnosis

Diagnosis is a combination of clinical recognition and targeted laboratory testing.

1. Clinical examination

• Visual inspection of the palms for characteristic yellow‑orange plaques.
• Dermatoscopy may show a homogeneous yellow structure without vascular patterns.
• Palpation confirms the firm yet mobile nature of the lesions.

2. Laboratory evaluation

• Lipid profile: fasting total cholesterol, LDL‑C, HDL‑C, triglycerides, and VLDL.
• Apolipoprotein E genotype testing if type III hyperlipoproteinemia is suspected.
• Blood glucose, HbA1c, and liver/kidney function tests to assess secondary causes.

3. Imaging (if needed)

• Ultrasound of carotid arteries – to detect early atherosclerosis.
• Coronary calcium scoring (CT) – for cardiovascular risk stratification.

4. Histopathology (rarely required)

If the diagnosis is uncertain, a 4‑mm punch biopsy can be performed. Microscopic findings include:

• Dermal infiltrates of foamy macrophages (lipid‑laden histiocytes).
• Scattered multinucleated giant cells and occasional cholesterol clefts.

Staining with Oil‑Red O confirms intracellular lipid.

Treatment Options

The primary aim is to lower plasma lipid concentrations, which often leads to regression of the palmar plaques.

1. Pharmacologic therapy

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line for LDL‑C reduction; can lower LDL by 30–50 %.
• Fibrates (e.g., fenofibrate, gemfibrozil) – especially effective for high triglycerides.
• Niacin (nicotinic acid) – lowers VLDL and raises HDL; used when triglycerides remain elevated despite statin/fibrate.
• PCSK9 inhibitors (evolocumab, alirocumab) – for refractory hypercholesterolemia or familial hypercholesterolemia.
• Ezetimibe – blocks intestinal cholesterol absorption, useful as add‑on therapy.
• Omega‑3 fatty acids (prescription‑grade EPA/DHA) – lower triglycerides.

Goal lipid targets follow ACC/AHA 2023 guidelines: LDL‑C < 70 mg/dL for very high risk, triglycerides < 150 mg/dL.

2. Lifestyle modifications

• Diet: Mediterranean‑style diet rich in fish, nuts, olive oil, vegetables, and whole grains; limit saturated fat (< 7 % of total calories), trans fats, and refined carbs.
• Weight management: aim for a BMI < 25 kg/m²; modest 5‑% weight loss can improve triglycerides by 10–20 %.
• Physical activity: at least 150 min/week of moderate‑intensity aerobic exercise.
• Alcohol moderation: limit to ≤ 1 drink/day for women, ≤ 2 drinks/day for men (alcohol raises triglycerides).
• Smoking cessation: reduces cardiovascular risk and can improve HDL‑C.

3. Procedural / adjunctive options

• Lipid‑apheresis – extracorporeal removal of plasma lipids for patients with severe, refractory hypertriglyceridemia (e.g., triglycerides > 1000 mg/dL) or acute pancreatitis.
• Plasmapheresis – occasionally used in systemic lipid disorders with rapid plaque progression.
• Surgical excision – rarely indicated; lesions may recur if underlying lipid abnormality persists.

4. Follow‑up

Re‑check lipid panel 4–8 weeks after therapy initiation, then every 3–6 months. Clinical inspection of the palms should be documented at each visit; improvement typically begins within 3–6 months of effective lipid control.

Living with Xanthoma of the Palmar Creases

While the lesions themselves are benign, they can affect self‑image and daily function. Practical tips:

• Skin care: keep palms moisturized with non‑comedogenic creams to avoid cracking. Avoid harsh soaps that strip natural oils.
• Protective gloves: use silicone or cotton gloves during activities that exert pressure on the palms (e.g., gardening, weight‑lifting) to lessen discomfort.
• Hand hygiene: regular washing reduces secondary infection risk if plaques become fissured.
• Regular monitoring: keep a log of any changes in size, color, or symptoms; share with your clinician.
• Psychological support: if lesions cause distress, consider counseling or support groups for patients with visible skin conditions.

Prevention

Because most cases stem from dyslipidemia, prevention focuses on maintaining healthy lipid levels:

• Screen cholesterol at least once every 4–6 years in adults ≥ 20 years (earlier if family history).
• Adopt a heart‑healthy diet from childhood.
• Encourage regular physical activity in the whole family.
• Promptly treat secondary causes (e.g., diabetes, hypothyroidism, nephrotic syndrome).
• Genetic counseling for families with known APOE ε2/ε2 or FH mutations.

Complications

If the underlying lipid disorder remains untreated, the following complications may arise:

• Atherosclerotic cardiovascular disease – premature coronary artery disease, myocardial infarction, stroke.
• Acute pancreatitis – especially when triglycerides exceed 1000 mg/dL.
• Peripheral vascular disease – claudication, ulceration.
• Eye involvement – corneal arcus, which can impair vision in severe cases.
• Psychosocial impact – anxiety or depression due to cosmetic concerns.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Xanthomas.” 2022; American College of Cardiology/American Heart Association 2023 cholesterol guidelines; National Institutes of Health (NIH) Lipid Research Clinics; Centers for Disease Control and Prevention (CDC) – Lipid disorders; Cleveland Clinic – Familial hyperlipidemia; World Health Organization (WHO) – Non‑communicable disease risk factor data. © 2026 SymptomChecker.com.

```